Sharemaestro company-news research for Ascelia Pharma AB (publ) (ACE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
STO
Sweden
Provisional evidence
Company news sentiment
Latest ACE news and sentiment
Ascelia Pharma AB (publ)
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Early balanced news score
21/100 evidence confidence
78% direct company focus
1 current stories across 1 publishers
Current company news
Early balanced news score
1 company-specific story are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone58/100
→
Published 30-day score51/100
Latest source headline
Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
finance.yahoo.com · 10 Sep 2026 05:45
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
1 current stories are mapped specifically to ACE.
What limits the score
Only 1 publisher currently contribute to the measured read.
Confidence is 21/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
21/100
Confidencethin evidence
78%/100
Company news1 company stories
N/A/100
Story agreementrequires at least 2 stories
News history
Daily score and story count over 30 days
18 Aug02 Sep16 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.063 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness35
recency-weighted evidenceAgreement0
requires at least 2 storiesPublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks11 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
20 Mar16 Jun11 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
11 Sep 202651SEK 0.637-0.8%
04 Sep 202650SEK 0.642+1.7%
28 Aug 202650SEK 0.631+3.4%
21 Aug 202650SEK 0.61+6.1%
14 Aug 202650SEK 0.575-4.0%
07 Aug 202650SEK 0.599+12.4%
31 Jul 202650SEK 0.533+5.8%
24 Jul 202650SEK 0.504+2.9%
Provisional evidence
News subjects
What is shaping the score
Regulatory and legal581 stories · 100%
Source mix
Where the evidence comes from
finance.yahoo.com581 stories · 100%
Recurring subjects
Subjects appearing most often
Regulation1Fda1Biotech1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
03 Jul50 neutral14 Sep 03:21
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Sep 03:21 | 51 | +0 | 23/100 (-4) | 1 (0) | Provisional |
| 10 Sep 23:59 | 51 | +1 | 27/100 (+12) | 1 (-4) | Provisional |
| 11 Aug 23:59 | 50 | +2 | 15/100 (-8) | 5 (-1) | Provisional |
| 02 Aug 23:59 | 48 | +1 | 23/100 (-4) | 6 (+1) | Provisional |
| 01 Aug 23:59 | 47 | -3 | 27/100 (+13) | 5 (+1) | Provisional |
| 23 Jul 23:59 | 50 | +0 | 14/100 (-3) | 4 (+1) | Provisional |
| 10 Jul 23:59 | 50 | +0 | 17/100 (-6) | 3 (+1) | Provisional |
| 05 Jul 23:59 | 50 | +0 | 23/100 (-5) | 2 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#158Tone
finance.yahoo.comDirect company coverageStored article
Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA
MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, regarding the Complete Response Letter (CRL) for the Orviglance® New Drug Application (NDA). The meeting provided an opportunity to discuss the issues raised by the FDA in the CRL and to gain further clarity regarding obtaining regulatory approval for Orviglance in the US. Ascelia will provide an update on the regulatory path forward after receiving the FDA's official meeting minutes. The minutes are
BiotechFdaRegulation
- Published
- 10 Sep 2026 05:45
- News subject
- Regulatory and legal
- Why this score
- Regulatory Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 44/100
- 30-day weight
- 100% of the score · 6.0d old
- Duplicates
- 1 consolidated
Earlier company news
ACE news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 6 older ACE headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ACE, but the headline and available text are not mainly about Ascelia Pharma AB (publ). They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ACE sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.